# AstraZeneca Plc Tezspire meets primary endpoints in WAYPOINT trial

- Link: https://www.directorstalkinterviews.com/astrazeneca-plc-tezspire-meets-primary-endpoints-in-waypoint-trial/4121176565
- Published: 2024-11-08T08:33:24+00:00
- Author: Amilia Stone

Positive high-level results from the Phase III WAYPOINT trial in patients with chronic
rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) showed that **[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
and Amgen’s _Tezspire_ (tezepelumab) demonstrated a statistically significant and
clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion
compared to placebo.

WAYPOINT is a randomised, double-blind trial that evaluated the efficacy and safety
of _Tezspire_ administered subcutaneously compared to placebo in adults with severe
CRSwNP. Participants in the trial were symptomatic despite treatment with standard
of care (intranasal corticosteroids [INCS]).^(1)

> **Dr. Joseph Han, Vice Chair of Rhinology & Endoscopic Sinus and Skull Base Surgery,
> and Allergy, Otolaryngology-Head and Neck Surgery, Eastern Virginia Medical School,
> US, and co-primary investigator in the trial, said,** “Chronic rhinosinusitis 
> with nasal polyps negatively impact patients’ daily lives with obstructions leading
> to disturbances in smell, taste and sleep as well as pain and fatigue. The impressive
> data from the WAYPOINT trial demonstrate tezepelumab’s potential as a new treatment
> for patients whose lives are disrupted by this debilitating disease.”

> **Dr. Brian Lipworth, Professor of Allergy and Pulmonology, Scottish Centre for
> Respiratory Research, and Tayside Rhinology Ear, Nose and Throat Clinic, Ninewells
> Hospital University of Dundee in Scotland, UK, and co-primary investigator in 
> the trial, said,** “Patients diagnosed with nasal polyps continue to experience
> significant burden including repeat surgeries and frequent treatment with high
> doses of oral corticosteroids, which are associated with serious systemic side
> effects. The tezepelumab data are clinically meaningful and offer patients with
> nasal polyps hope for a potential new treatment option that may reduce the burden
> on patients and healthcare systems.”

> **Sharon Barr, Executive Vice President, AstraZeneca BioPharmaceuticals R&D said**:“
> We are excited by the positive results from the Phase III WAYPOINT trial, which
> show that patients with nasal polyps strongly benefitted from treatment with tezepelumab.
> These results reinforce that tezepelumab’s first-in-class mode of action, targeting
> TSLP at the top of the inflammatory cascade, effectively addresses the multiple
> drivers of epithelial-driven inflammatory diseases.”

The safety profile and tolerability of _Tezspire_ in this trial were consistent 
with the known profile of the medicine.

Full results will be shared with regulatory authorities and the scientific community
at an upcoming medical meeting.

_Tezspire_ is currently approved for the treatment of severe asthma in the US, EU,
Japan, and nearly 60 countries across the globe.^(2-5) It is approved as a single-
use pre-filled syringe and auto-injector for self-administration in the US and EU.
^(2,3)

**Amgen collaboration** 

In 2020, Amgen and AstraZeneca updated a 2012 collaboration agreement for _Tezspire_.
Both companies will continue to share costs and profits equally after payment by
AstraZeneca of a mid single-digit inventor royalty to Amgen. AstraZeneca continues
to lead development and Amgen continues to lead manufacturing. All aspects of the
collaboration are under the oversight of joint governing bodies. Under the amended
agreement, Amgen and AstraZeneca will jointly commercialise _Tezspire_ in North 
America. Amgen will record product sales in the US, with AZ recording its share 
of US profits as Collaboration Revenue. Outside of the US, AstraZeneca will record
product sales, with Amgen recording profit share as Other/Collaboration revenue.

References

 1. Clinicaltrials.gov. Efficacy and Safety of Tezepelumab in Participants With Severe
    Chronic Rhinosinusitis With Nasal Polyposis (WAYPOINT). Available at: https://clinicaltrials.
    gov/ct2/show/NCT04851964. [Last accessed: November 2024].
 2. Tezspire (tezepelumab) US prescribing information. Available at: https:// www.accessdata.
    fda.gov/drugsatfda_docs/label/2023/761224s003lbl.pdf. [Last accessed: November 
    2024].
 3. Tezspire (tezepelumab) Summary of Product Characteristics. Available at: https://
    www.ema.europa.eu/en/documents/product-information/tezspire-epar-product-information_en.
    pdf. [Last accessed: November 2024].
 4. AstraZeneca plc. Tezspire approved in Japan for the treatment of severe asthma.
    Available at: https://www.astrazeneca.com/media-centre/press-releases/2022/tezspire-
    approved-in-japan-for-severe-asthma.html [Last accessed: November 2024].
 5. Data on File. AstraZeneca. 2024. REF-251231.

Share on:
